

(R)-4-(3-(3-(azetidin-1-yl)pyrrolidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-(pyrrolidin-1-ylmethyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-(piperidin-1-ylmethyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-(azetidin-1-ylmethyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-((cyclopropylamino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-((isopropylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-(((cyclopropylmethyl)amino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-((isobutylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-((cyclobutylamino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride; and  
 4-(4-fluoro-3-(3-((prop-2-yn-1-ylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride.

[Claim 8] A pharmaceutical composition for treating cancers comprising the compound according to any one of claims 1-7.

[Claim 9] The pharmaceutical composition according to claim 8, wherein the cancers are caused by genetic defect of BRCA1, BRCA2, and ERG fusion gene.

[Claim 10] The pharmaceutical composition according to claim 9, wherein the cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, colorectal cancer, brain tumor, prostate cancer and Ewing's sarcoma.

~~[Claim 11] A method of treating cancers in a subject in need thereof, comprising administering an effective amount of the compound according to any one of claims 1-7 to the subject.~~

~~[Claim 12] The method according to claim 11, wherein the cancers are caused by genetic defect of BRCA1, BRCA2, and ERG fusion gene.~~

~~[Claim 13] The method according to claim 12, wherein the cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer,~~

- colorectal cancer, brain tumor, prostate cancer and Ewings sarcoma.
- [Claim 14] A use of the compound according to any one of claims 1-7 for manufacturing a medicament for treating cancers.
- [Claim 15] The use according to claim 14, wherein the cancers are caused by generic defect of BRCA1, BRCA2, and ERG fusion gene.
- [Claim 16] The use according to claim 15, wherein the cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, colorectal cancer, brain tumor, prostate cancer and Ewings sarcoma.

(R)-4-(3-(3-(azetidin-1-yl)pyrrolidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-(pyrrolidin-1-ylmethyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-(piperidin-1-ylmethyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-(azetidin-1-ylmethyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-((cyclopropylamino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-((isopropylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-(((cyclopropylmethyl)amino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(4-fluoro-3-(3-((isobutylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride;  
 4-(3-(3-((cyclobutylamino)methyl)azetidine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride; and  
 4-(4-fluoro-3-(3-((prop-2-yn-1-ylamino)methyl)azetidine-1-carbonyl)benzyl)phthalazin-1(2H)-one hydrochloride.

- [Claim 8] A pharmaceutical composition for treating cancers comprising the compound according to any one of claims 1-7.
- [Claim 9] The pharmaceutical composition according to claim 8, wherein the cancers are caused by genetic defect of BRCA1, BRCA2, and ERG fusion gene.
- [Claim 10] The pharmaceutical composition according to claim 9, wherein the cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, colorectal cancer, brain tumor, prostate cancer and Ewing's sarcoma.
- [Claim 11] A use of the compound according to any one of claims 1-7 for manufacturing a medicament for treating cancers.
- [Claim 12] The use according to claim 11, wherein the cancers are caused by genetic defect of BRCA1, BRCA2, and ERG fusion gene.
- [Claim 13] The use according to claim 12, wherein the cancers are selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, gastric cancer, lung cancer, colorectal cancer, brain tumor, prostate cancer and Ewing's sarcoma.